• Publications
  • Influence
(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
TLDR
An overview of design and development of (18)F-labeled PET radiopharmaceuticals, radiochemistry, and mechanism(s) of tumor cell uptake and localization of radiotracers are presented here. Expand
Possible axonal regrowth in late recovery from the minimally conscious state.
TLDR
It is proposed that axonal regrowth may underlie these findings and provide a biological mechanism for late recovery and is discussed in the context of recent experimental studies that support this inference. Expand
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
TLDR
Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation. Expand
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
TLDR
Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of (90)Y-J591 in the treatment of patients with PC. Expand
Nutrient patterns and brain biomarkers of Alzheimer’s disease in cognitively normal individuals
TLDR
Specific dietary NPs are associated with brain biomarkers of AD in NL individuals, suggesting that dietary interventions may play a role in the prevention of AD by modulating AD-risk through its effects on Aβ and associated neuronal impairment. Expand
Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
TLDR
A single dose of 177Lu-J591 was well tolerated with reversible myelosuppression and accurate tumor targeting and PSA responses were seen with evidence of dose response. Expand
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
TLDR
The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. Expand
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
TLDR
Compared with the standard-of-care bone scanning, 99mTc-MIP-1404 and 99mMip-1405 identified most bone metastatic lesions and rapidly detected soft-tissue PCa lesions including subcentimeter lymph nodes. Expand
Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer’s
TLDR
Children of parents with LOAD, particularly those with affected mothers, have increased fibrillar Aβ load in AD-vulnerable regions compared with controls, perhaps accounting for the known increased risk for AD. Expand
Prostate-specific membrane antigen-based imaging.
TLDR
Ab and small molecule imaging exemplified by PSMA targeting have the greatest potential to improve diagnostic sensitivity and specificity in CaP imaging. Expand
...
1
2
3
4
5
...